



Franklin Biotechnology Discovery Fund A

(acc) EUR-H1

Sector LU1803069274 Factsheet as of 31 March 2024


This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID/KIID before making any final investment decisions.

Investment Overview

The Fund is classified as Article 8 under EU Sustainable Finance Disclosure Regulation and aims to increase the value of its investments over the medium to long term. The Fund pursues an actively managed investment strategy and invests mainly in equity securities issued by biotechnology companies of any size located in the U.S. and other countries.

Past performance does not predict future returns.

Performance Over 5 Years in Share Class Currency (%)



Discrete Annual Performance (%)

	03/23	03/22	03/21	03/20	03/19	03/18	03/17	03/16	03/15	03/14
	03/24	03/23	03/22	03/21	03/20	03/19	03/18	03/17	03/16	03/15
A (acc) EUR-H1	27.80	-6.39	-22.01	38.52	-4.99	—	—	—	—	—
Benchmark (USD)	7.39	-0.98	-11.83	39.29	-3.42	—	—	—	—	—

Total Returns (%)

	Cumulative					Average Annual					Inception Date
	1-Mo	3-Mo	YTD	1-Yr	3-Yr	5-Yr	Inception	3-Yr	5-Yr	Inception	
A (acc) EUR-H1	-1.72	11.46	11.46	27.80	-6.69	22.80	25.50	-2.28	4.19	3.87	6/4/2018
Benchmark (USD)	0.03	1.36	1.36	7.39	-6.24	26.13	39.46	-2.13	4.75	5.71	—

The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested.

Performance details provided are in share class currency, include the reinvested dividends gross of tax and are net of management fees. Sales charges, taxes and other locally applied costs have not been deducted. The fund's returns may increase or decrease as a result of changes to foreign exchange rates.

Up to date performance figures can be found on our website.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Fund Overview

Fund Base Currency	USD
Fund Inception Date	03/04/2000
Share Class Inception Date	06/04/2018
ISIN	LU1803069274
Sedol	BFXW2Q7
Valor Number	41187139
Bloomberg	FTBAEH1 LX
EU SFDR Category	Article 8
Minimum Investment	USD 1000

Benchmark(s) and Type

NASDAQ Biotechnology Index	Comparator
----------------------------	------------

Charges

Maximum Initial Charge	5.75%
Exit Charge	—
Ongoing Charges Figure	1.81%
Performance Fee	—

The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Fund Characteristics

	Fund
NAV-A (acc) EUR-H1	€12.55
Total Net Assets	\$1.79 Billion
Number of Issuers	86
Average Market Cap (Millions USD)	\$39,857
Historical EPS Growth (3 Yr)	2.06%
Estimated 3-5 Year EPS Growth	-16.02%
Price to Earnings (12 Month Forward)	15.53x
P/E to Growth	2.21x
Standard Deviation (5 Yr)	21.14%

Top Equity Issuers (% of Total)

	Fund
AMGEN INC	6.85
REGENERON PHARMACEUTICALS INC	6.43
VERTEX PHARMACEUTICALS INC	5.35
ASCENDIS PHARMA A/S	4.22
GILEAD SCIENCES INC	3.07
ASTRAZENECA PLC	3.01
BIOGEN INC	2.88
APPLIED THERAPEUTICS INC	2.71
JAZZ PHARMACEUTICALS PLC	2.67
INTRA-CELLULAR THERAPIES INC	2.62

Sector Allocation (% of Total)

	Fund
Biotechnology	77.72
Pharmaceuticals	15.67
Life Sciences Tools & Services	4.52
Health Care Services	0.81
Health Care Facilities	0.08
Cash & Cash Equivalents	1.20

Market Cap Breakdown (% of Equity) (USD)

	Fund
<2.0 Billion	30.00
2.0-5.0 Billion	17.81
5.0-10.0 Billion	12.07
10.0-25.0 Billion	10.07
25.0-50.0 Billion	3.70
>50.0 Billion	25.89
N/A	0.45

Portfolio Management

	Years with Firm	Years of Experience
Evan McCulloch, CFA	31	32
Wendy Lam, PhD	8	12
Akiva Felt	5	17

What are the Risks?

The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: **Liquidity risk:** the risk that arises when adverse market conditions affect the ability to sell assets when necessary. Such risk may be triggered by (but not limited to) unexpected events such as environmental disasters or pandemics. Reduced liquidity may have a negative impact on the price of the assets. **Equity risk:** prices of equities may be affected by factors such as economic, political, market, and issuer-specific changes. Such changes may adversely affect the value of the equities regardless of company-specific performance. **Securities Lending risk:** the risk that default or insolvency of the borrower of securities lent by a Fund may lead to losses if collateral received realises less than the values of securities lent. Complete information on the risks of investing in the Fund are set out in the Fund's prospectus.

Glossary

Ongoing Charges Figure (OCF): The Ongoing Charges Figure (OCF) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The OCF is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The OCF does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, where applicable, see the KID/KIID. **Comparator:** Benchmark is used for comparing Fund performance, but is not a constraint to Fund Investment. **Historical 3 Yr EPS Growth:** A measure of the growth of earnings per share over a trailing 3 year period. For a portfolio, the value represents a weighted average of the stocks it holds. **Estimated 3-5 Yr EPS Growth:** An estimated measure of the growth of earnings per share over a forward-looking period. For a portfolio, the value represents a weighted average of the stocks it holds. **P/E (12-month Forward):** A measure of the price to earnings ratio for a stock using the forecasted earnings for the next 12 months. For a portfolio, the value represents a weighted average of the stocks it holds. **P/E to Growth:** A ratio used to determine a stock's value while taking into account earnings growth. For a portfolio, the value represents a weighted average of the stocks it holds. **Standard Deviation:** Measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will fluctuate from the average return.

Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

Important Information

This Fund has been classified as Article 8 under the Regulation on sustainability related disclosures in the financial services sector (EU) 2019/2088. These are Funds which have an ESG integration approach and, in addition, have binding environmental and/or social characteristics in their investment process.

Further information in relation to the sustainability-related aspects of the Fund can be found at www.franklintempleton.lu/SFDR. Please review all of the Fund's objectives and characteristics before investing. This is a sub-fund ("Fund") of Franklin Templeton Investment Funds ("FTIF"), a Luxembourg registered SICAV. Subscriptions to shares of the Fund can only be made based on the Fund's current Prospectus and, where available, the relevant Key Information Document ("KID") / Key Investor Information Document ("KIID"), accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. These documents can be found on our website at www.ftidocuments.com, obtained, free of charge, from your local FT representative or can be requested via FT's European Facilities Service which is available at <https://www.eifs.lu/franklintempleton>. The Fund's documents are available in English, Arabic, French, German, Italian, Polish and Spanish. In addition, a summary of investor rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English. The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you decide to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.

Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser.

The share class shown has adopted a hedging strategy intended to reduce the effect of exchange rate movements between the currency of the Fund's investment strategy and the currency of the share class. The benchmark returns displayed are shown in the reference currency of the Fund's investment strategy USD, while share class returns are shown in the reference currency of share class EUR. As a result, the returns shown above reflect the effect of the hedging strategy and one can compare the returns of the Fund (net of fees) relative to its benchmark index without the impact of exchange rate movements on index returns.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

© Morningstar, Inc. All rights reserved. The information contained here in (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

In Europe (excluding Poland & Switzerland), this financial promotion is issued by Franklin Templeton International Services S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg - Tel: +352-46 66 67-1 - Fax: +352-46 66 76. **In Switzerland**, issued by Franklin Templeton Switzerland Ltd, Stockerstrasse 38, CH-8002 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. **In Poland**, Templeton Asset Management (Poland) TFI S.A.; Rondo ONZ 1; 00-124 Warsaw. **In the Middle East**, issued by Franklin Templeton Investments (ME) Limited, authorized and regulated by the Dubai Financial Services Authority. Franklin Templeton Investments, The Gate, East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E., Tel: +9714-4284100 Fax: +9714-4284140. **In Canada**, this material may be distributed in Canada by Franklin Templeton Investments Corp. **UK contact information**, UK Freephone: 0800 305 306 | email: enquiries@franklintempleton.co.uk | www.franklintempleton.co.uk

© 2024 Franklin Templeton. All rights reserved.